|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Anesthesiology, University of North Carolina, Chapel Hill, North Carolina 27599
Submitted 16 September 2003 ; accepted in final form 2 December 2003
| ABSTRACT |
|---|
|
|
|---|
reactive oxygen species; guanylyl cyclase; cGMP-dependent protein kinase; mitochondrial ATP-sensitive potassium channel; extracellular signal-regulated kinase; phosphatidylinositol 3-kinase
As to the mechanism for the cardioprotective effect of NO, cGMP (13, 25) and reduced mitochondrial calcium uptake (26) have been suggested to be possible mechanisms of the protection. Recently, reactive oxygen species (ROS) have been reported to be essential in the cardioprotective effect of NO. In late preconditioning, NO induces production of ROS, which in turn activate PKC (3, 21, 29, 30). Similar to findings from the late preconditioning studies, the SNAP-induced anti-infarct effect was abrogated by N-(2-mercaptopropionyl)glycine (MPG), an inhibitor of ROS, suggesting an involvement of ROS in the protection in rabbit heart (14). However, the role of ROS in the protection of NO was based on indirect evidence that the protection was aborted by MPG, without showing direct evidence that comes from measurement of ROS. Moreover, it is intriguing to investigate the mechanism by which NO induces ROS generation, if ROS are indeed involved in NO's action.
Opening of mitochondrial ATP-sensitive potassium (KATP) channels has been demonstrated to trigger ischemic preconditioning by generation of ROS (7, 17, 19). In rabbit cardiomyocytes, acetylcholine causes generation of ROS by opening mitochondrial KATP channels (17). Interestingly, it was reported that exogenous NO activates mitochondrial KATP channels in rabbit cardiomyocytes (10, 27). Therefore, we hypothesized that opening of mitochondrial KATP channels by NO is an essential step to cause ROS generation. Furthermore, if mitochondrial KATP channel opening is crucial for NO-induced ROS production, it is intriguing to investigate the signaling pathway by which NO causes KATP channel opening. Recently, it was reported that exogenous NO and cGMP-dependent protein kinase (PKG) activate KATP channels in rabbit ventricular myocytes (10). Thus we determined whether the NO-cGMP-PKG pathway is involved in the mechanism of ROS generation.
In addition, very little information is available about the signal cascade beyond ROS in the protective effect of NO (or SNAP). ERK has been reported to be involved in ischemic preconditioning (8, 22, 28) and antiapoptotic pathways (34). ROS, especially H2O2, can induce ERK activation (1, 15). Therefore, if SNAP acts through ROS, it is important to test whether ERK is a component of the signal cascade for the protection of SNAP. Because phosphatidylinositol 3-kinase (PI3-kinase) has been implicated in the mechanism for ischemic preconditioning (31) and ERK activation by ROS (15), PI3-kinase may also contribute to the protection of SNAP.
In the present study, we first observed whether SNAP could induce ROS generation in isolated rat cardiomyocytes and whether PKG and mitochondrial KATP channels were involved in SNAP-induced ROS generation. We then observed the roles of ROS and mitochondrial KATP channels in the anti-infarct effect of SNAP. Finally, we examined whether ERK and PI3-kinase were involved in SNAP's protection.
| METHODS |
|---|
|
|
|---|
Isolation of adult rat cardiomyocytes. Male Wistar rats weighing 250350 g were anesthetized with thiobutabarbital sodium (100 mg/kg). A central thoracotomy was performed, and the heart was removed and rapidly mounted on a Langendorff apparatus. The heart was perfused in a nonrecirculating mode with Krebs-Henseleit buffer (37°C) containing (in mM) 118 NaCl, 25 NaHCO3, 4.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, 1.25 CaCl2, and 10 glucose for 5 min to wash out blood. The buffer was bubbled with 95% O2-5% CO2. The heart was then perfused with calcium-free buffer that contained the above components except for CaCl2. After 5 min of perfusion, collagenase (type II, Worthington Biochemical) was added to the buffer (0.1%) and the heart was perfused in a recirculating mode for
15 min. The heart was removed from the apparatus, and the ventricles were placed into a beaker containing the calcium-free buffer. The ventricles were agitated in a shaking bath (37°C) at a rate of 50 cycles/min until cells were released. The released cells were suspended in an incubation buffer containing all the components of the calcium-free buffer, 1% bovine serum albumin, 30 mM HEPES, 60 mM taurine, 20 mM creatine, and amino acid supplements at 37°C. Calcium was gradually added to the buffer containing the cells to a final concentration of 1.2 mM. The cells were filtered through nylon mesh and centrifuged briefly. Finally, the cells were suspended in culture medium 199 (no. 7653, Sigma) for 4 h before experiments.
Measurement of intracellular ROS. Cardiomyocytes cultured on a 24-well tissue culture plate were incubated with 20 µM dichlorodihydrofluorescein diacetate (H2DCFDA) at 37°C for 20 min. After being washed with PBS, the cells were incubated in standard Tyrode solution including (in mM) 140 NaCl, 6 KCl, 1 MgCl2, 5 HEPES, 1.8 CaCl2, and 5.8 glucose (pH 7.4) for ROS measurement. Dichlorofluorescein (DCF) fluorescence was measured with a fluorescent plate reader (SpectraMAX GeminiXS, Molecular Probes). The fluorescence was excited at 480 nm and collected at 530 nm. The change in fluorescent intensity for each experimental group was expressed as a percentage of respective control value. Temperature was maintained at 37°C throughout the experiment.
Perfusion of isolated rat heart. Male Wistar rats (280350 g) were anesthetized with thiobutabarbital sodium (100 mg/kg ip). The hearts were removed rapidly and mounted on a Langendorff apparatus. The hearts were perfused with Krebs-Henseleit buffer containing (in mM) 118.5 NaCl, 4.7 KCl, 1.2 MgSO4, 1.8 CaCl2, 24.8 NaHCO3, 1.2 KH2PO4, and 10 glucose, which was heated to 37°C and gassed with 95% O2-5% CO2. A latex balloon connected to a pressure transducer was inserted into the left ventricle through the left atrium. The left ventricular pressure and heart rate were continuously recorded with a PowerLab system (ADInstruments, Mountain View, CA). A 5-0 silk suture was placed around the left coronary artery. The ends of the suture were passed through a small piece of soft vinyl tubing to form a snare. All hearts were allowed to stabilize for at least 20 min. Ischemia was induced by pulling the snare and then fixing it by clamping the tubing with a small hemostat. Total coronary artery flow was measured by timed collection of the perfusate dripping from the heart into a graduated cylinder.
Measurement of infarct size. At the end of the experiments, the coronary artery was reoccluded and fluorescent polymer microspheres (2- to 9-µm diameter, Duke Scientific) were infused to demarcate the risk zone as the tissue without fluorescence. The hearts were weighed, frozen, and cut into 1-mm slices. The slices were incubated in 1% triphenyltetrazolium chloride (TTC) in sodium phosphate buffer at 37°C for 20 min. The slices were immersed in 10% formalin to enhance the contrast between stained (viable) and unstained (necrotic) tissue and then squeezed between glass plates spaced exactly 1 mm apart. The myocardium at risk was identified by illuminating the slices with UV light. The infarcted and risk zone regions were traced on a clear acetate sheet and quantified with ImageTool. The areas were converted into volumes by multiplying the areas by slice thickness. Infarct size is expressed as a percentage of the risk zone.
Western blotting analysis of phosphorylated ERK activity. After exposure to SNAP for 30 min, cells were homogenized in ice-cold lysis buffer. Equal amounts of protein were loaded and electrophoresed on 10% SDS-polyacrylamide gel and transferred to a polyvinylidene difluoride membrane. The membrane was probed with the primary antibody that recognizes phospho-p42/p44 MAPK (phospho-ERK). To confirm equal loading, the membrane was stripped and reprobed with an antibody recognizing both phosphorylated and nonphosphorylated forms of p42/p44 MAPK. The primary antibody binding was detected with a secondary anti-rabbit antibody and visualized by the enhanced chemiluminescence method.
Experimental protocols. The agonists and antagonists used in the studies are described in Table 1. In the ROS measurement study, the cells were treated with 20 µM SNAP for 20 min. YC-1 and 8-bromoguanosine 3',5'-cyclic monophosphate (8-BrcGMP) were given for 20 min. The blockers were given 10 min before SNAP and were present throughout the experiment. In the isolated, perfused heart study, all hearts were subjected to a 30-min sustained ischemia followed by 2 h of reperfusion. Infusion of SNAP (10 µM) was started 30 min before ischemia and lasted for 20 min. The blockers MPG (300 µM), 5-hydroxydecanoate (5-HD), PD-98059 (20 µM), and LY-294002 (10 µM) were administered for 30 min, starting 5 min before the infusion of SNAP. To measure ERK activity with Western blotting, myocytes were treated with SNAP (10 and 100 µM) for 30 min and then processed as described above. To observe the relationship between ROS and ERK in the action of SNAP, we performed another series of ERK studies in which MPG (0.5 mM) was given 10 min before the treatment with SNAP.
|
Statistics. All data are expressed as means ± SE. One-way ANOVA followed by Tukey's test was used to test for differences in baseline hemodynamics, infarct size, fluorescence values, and phospho-ERK activity among groups. A P value of <0.05 was considered to be statistically significant.
| RESULTS |
|---|
|
|
|---|
|
|
|
|
|
|
|
Infarct size study. Baseline heart rate, left ventricular developed pressure, and coronary flow were not different among any of the experimental groups (Table 2). There were no significant differences in body weight, heart weight, or the size of the risk zone among the groups (Table 3). Infarct size in the control hearts was 36.8 ± 3.6% of the risk zone (Fig. 8). Pretreatment with 10 µM SNAP significantly reduced infarct size to 14.8 ± 1.5% of the risk zone (P < 0.05). The anti-infarct effect of SNAP was assessed in hearts treated with MPG, a ROS scavenger. As shown in Fig. 8, the protective effect of SNAP was completely blocked by 300 µM MPG (35.1 ± 3.6% infarction of the risk zone), suggesting an involvement of ROS in the protection of SNAP in isolated rat hearts. MPG alone did not affect infarct size. The anti-infarct effect of SNAP was also abolished by closing mitochondrial KATP channels with 500 µM 5-HD (34.1 ± 2.0% infarction of the risk zone), indicating that opening of mitochondrial KATP channels is needed for cardioprotection by SNAP. The ERK inhibitor PD-98059 (20µM) was used to test whether the ERK pathway is involved in the protection. The anti-infarct effect of SNAP was totally reversed by 20 µM PD-98059 (31.7 ± 1.4% infarction of the risk zone), as shown in Fig. 9. PD-98059 alone did not affect infarct size (33.1 ± 3.0% infarction of the risk zone). The PI3-kinase inhibitor LY-294002 (10 µM) did not alter the protective effect of SNAP (13.9 ± 1.4% infarction of the risk zone). These results suggest that SNAP protects the hearts from ischemia-reperfusion injury through ROS and ERK pathways but not through PI3-kinase.
|
|
|
|
Western blotting analysis of ERK activity. The cardiomyocytes were incubated with SNAP (10 and 100 µM) for 30 min. As shown in Fig. 10, treatment with 10 µM SNAP resulted in a significant increase in activities in phosphorylated ERKs (134.2 ± 13.5% of the control in ERK1 and 134.9 ± 12.8% in ERK2; P < 0.05 vs. control). ERK1 and -2 activities were further increased by 100 µM SNAP to 182.3 ± 22.4% and 187.7 ± 23.1% of control, respectively. In another series of experiments, the increased phospho-ERK activities were reversed by 1 mM MPG, indicating that SNAP activated ERK through ROS generation (Fig. 11). These results further suggest that ERK is an important element of the signal pathway leading to cardioprotection by SNAP.
|
|
| DISCUSSION |
|---|
|
|
|---|
In the present study, we demonstrated that SNAP-induced ROS generation was blocked by the PKG inhibitor KT-5823, implying that PKG is needed for SNAP-induced ROS generation. To further confirm the role of PKG in ROS generation, we examined whether direct activation of PKG with 8-BrcGMP could result in ROS production. Our data clearly show that 8-BrcGMP significantly increases ROS generation, supporting the concept that SNAP induces ROS generation via activation of PKG. Furthermore, 8-BrcGMP-induced ROS generation was also reversed by 5-HD, confirming that PKG induces ROS generation through activation of mitochondrial KATP channels. Because NO activates PKG via a GC-cGMP pathway, we then tested whether activation of GC could duplicate PKG's effect. Similar to PKG, activation of GC with YC-1 significantly increased ROS generation and this effect was dependent on mitochondrial KATP channel opening. Thus our data would suggest a unique signal pathway leading to ROS generation: NO-GC-cGMP-PKG-mitochondrial KATP channel opening-ROS production. Similarly, Han et al. (10) reported that the cGMP-PKG pathway is involved in phosphorylation of KATP channels in rabbit cardiomyocytes.
The present investigation identifies ERK as a likely downstream target of ROS in SNAP-induced protection. ERK has been proposed to participate in preconditioning (8, 28) and antiapoptosis action (34). ROS are known to activate ERK (9, 15). Aikawa et al. (1) reported that H2O2 rapidly and transiently activated ERK in rat cardiomyocytes. In their study, 0.01 mM (10 µM) H2O2 for 10 min significantly increased ERK activity. The dose and duration of H2O2 treatment were quite similar to those of another study in which 15 µM H2O2 for 10 min mimicked the preconditioning effect in chick cardiomyocytes (32). In the current study, the anti-infarct effect of SNAP was blocked by the MEK inhibitor PD-98059 and ERK was phosphorylated to its active catalytic form by treatment with SNAP. Furthermore, the enhanced phosphorylation of ERK by SNAP was blocked by MPG, suggesting that ROS serve as the upstream signal of ERK in SNAP's action. Therefore, we conclude that the increased ERK activity induced by ROS is responsible for the cardioprotective effect of SNAP.
PI3-kinase is involved in cell survival pathways and in metabolic control. Tong et al. (31) reported that the preconditioning effect was blocked by PI3-kinase inhibitors and that PI3-kinase is the upstream signal of PKC in the mechanism of preconditioning. Recently, Oldenburg et al. (18) reported that PI3-kinase is involved in the effect of acetylcholine on ROS production and proposed that a PI3-kinase step exists between the surface receptor and mitochondrial KATP channels. If their hypothesis is correct, PI3-kinase should be an upstream trigger of ROS because ROS production is dependent on the opening of KATP channels. In the present study, both LY-294002 and wortmannin affected neither the ROS-generating nor anti-infarct effects of SNAP, suggesting that SNAP's protection does not require PI3-kinase activation.
Finally, we summarize the signal pathway of SNAP's action in Fig. 12. SNAP can cause ROS generation, and ROS play a crucial role in the protective effect of SNAP. SNAP-induced ROS generation is dependent on opening of mitochondrial KATP channels, activation of PKG, and the direct inhibition of mitochondrial ETC. Although PI3-kinase is not involved, ERK activation appears to be the downstream signal of ROS in SNAP's action.
|
| ACKNOWLEDGMENTS |
|---|
This work was partially supported by American Heart Association Beginning Grant-In-Aid 0365534U (to Z. Xu).
| FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
| REFERENCES |
|---|
|
|
|---|
i and G
o are target proteins of reactive oxygen species. Nature 408: 492495, 2000.[CrossRef][Medline]
This article has been cited by other articles:
![]() |
D. E. Choi, J. Y. Jeong, B. J. Lim, S. Chung, Y. K. Chang, S. J. Lee, K. R. Na, S. Y. Kim, Y. T. Shin, and K. W. Lee Pretreatment of sildenafil attenuates ischemia-reperfusion renal injury in rats Am J Physiol Renal Physiol, August 1, 2009; 297(2): F362 - F370. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Das, F. N. Salloum, L. Xi, Y. J. Rao, and R. C. Kukreja ERK phosphorylation mediates sildenafil-induced myocardial protection against ischemia-reperfusion injury in mice Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1236 - H1243. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Girouard, G. Wang, E. F. Gallo, J. Anrather, P. Zhou, V. M. Pickel, and C. Iadecola NMDA Receptor Activation Increases Free Radical Production through Nitric Oxide and NOX2 J. Neurosci., February 25, 2009; 29(8): 2545 - 2552. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. T. Costa and K. D. Garlid Intramitochondrial signaling: interactions among mitoKATP, PKC{varepsilon}, ROS, and MPT Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H874 - H882. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Dezfulian, N. Raat, S. Shiva, and M. T. Gladwin Role of the anion nitrite in ischemia-reperfusion cytoprotection and therapeutics Cardiovasc Res, July 15, 2007; 75(2): 327 - 338. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Jang, H. Wang, J. Xi, R. A. Mueller, E. A. Norfleet, and Z. Xu NO mobilizes intracellular Zn2+ via cGMP/PKG signaling pathway and prevents mitochondrial oxidant damage in cardiomyocytes Cardiovasc Res, July 15, 2007; 75(2): 426 - 433. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Nowak, G. L. Clifton, M. L. Godwin, and D. Bakajsova Activation of ERK1/2 pathway mediates oxidant-induced decreases in mitochondrial function in renal cells Am J Physiol Renal Physiol, October 1, 2006; 291(4): F840 - F855. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Hausenloy and D. M. Yellon Survival kinases in ischemic preconditioning and postconditioning Cardiovasc Res, May 1, 2006; 70(2): 240 - 253. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hassouna, M. Loubani, B. M. Matata, A. Fowler, N. B. Standen, and M. Galinanes Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium Cardiovasc Res, February 1, 2006; 69(2): 450 - 458. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Okada, H. Otani, Y. Wu, T. Uchiyama, S. Kyoi, R. Hattori, T. Sumida, H. Fujiwara, and H. Imamura Integrated pharmacological preconditioning and memory of cardioprotection: role of protein kinase C and phosphatidylinositol 3-kinase Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H761 - H767. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. A. Reid, G. Kristo, Y. Yoshimura, C. Ballard-Croft, B. J. Keith, R. M. Mentzer Jr, and R. D. Lasley In vivo adenosine receptor preconditioning reduces myocardial infarct size via subcellular ERK signaling Am J Physiol Heart Circ Physiol, May 1, 2005; 288(5): H2253 - H2259. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kimura, G.-X. Zhang, A. Nishiyama, T. Shokoji, L. Yao, Y.-Y. Fan, M. Rahman, T. Suzuki, H. Maeta, and Y. Abe Role of NAD(P)H Oxidase- and Mitochondria-Derived Reactive Oxygen Species in Cardioprotection of Ischemic Reperfusion Injury by Angiotensin II Hypertension, May 1, 2005; 45(5): 860 - 866. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Sarre, N. Lange, P. Kucera, and E. Raddatz mitoKATP channel activation in the postanoxic developing heart protects E-C coupling via NO-, ROS-, and PKC-dependent pathways Am J Physiol Heart Circ Physiol, April 1, 2005; 288(4): H1611 - H1619. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Karliner Symbols within words: Have we neglected the AdeNOsine A2 receptor? Cardiovasc Res, March 1, 2005; 65(4): 763 - 765. [Full Text] [PDF] |
||||
![]() |
R. Furst, C. Brueckl, W. M. Kuebler, S. Zahler, F. Krotz, A. Gorlach, A. M. Vollmar, and A. K. Kiemer Atrial Natriuretic Peptide Induces Mitogen-Activated Protein Kinase Phosphatase-1 in Human Endothelial Cells via Rac1 and NAD(P)H Oxidase/Nox2-Activation Circ. Res., January 7, 2005; 96(1): 43 - 53. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |